Related Experiment Video
Updated: Nov 30, 2025
Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
Published on: July 8, 2025
Isovaline efficacy in a rat pup model of infantile spasms
Rohaan Manzoor1, Farah Malek2, Sohail Malek3
1Department of Neuroscience and Experimental Therapeutics, Albany Medical College.
Insights
Isovaline, an amino acid, shows promise in treating infantile spasms, a severe infant epilepsy. This study found isovaline significantly reduced seizure behaviors in a rat model, offering a potential new therapeutic avenue.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Infantile spasms are a severe epilepsy syndrome in infants and young children.
- This condition is linked to developmental issues and is often resistant to conventional treatments.
- A unique amino acid, isovaline, has previously demonstrated anticonvulsant properties.
Purpose of the Study:
- To investigate the therapeutic potential of isovaline in a validated rat model of infantile spasms.
- To assess isovaline's efficacy in reducing seizure activity induced by N-methyl-D-aspartate (NMDA).
Main Methods:
- A rat model of infantile spasms was established by prenatal betamethasone exposure and postnatal NMDA administration.
- Infant rat pups were treated with either saline or isovaline (300 mg/kg) before NMDA induction.
- Seizure behaviors, including full-body jumps, leg/arm/tail strains, body twitch, and head nods, were quantified.
Main Results:
- Isovaline significantly decreased the incidence of full-body jumps and leg/arm/tail strains compared to saline.
- A trend towards reduced body twitch was observed in the isovaline-treated group (P=0.05).
- No significant difference in NMDA-induced head nods was found between groups (P=0.221).
Conclusions:
- Isovaline demonstrates significant anticonvulsant effects in a rat model of infantile spasms.
- These findings suggest isovaline may be a potential therapeutic agent for this aggressive form of epilepsy.
- Further research is warranted to explore isovaline's utility in treating pediatric epilepsy, potentially offering an alternative to toxic medications.
Abstract:
Infantile spasms, also known as epileptic spasms during infancy, is an epileptic disorder of infancy and early childhood that is associated with developmental delay or regression, high mortality rate and is difficult to treat with conventional antiseizure medication. Previously, we reported that a unique amino acid called isovaline had potent anticonvulsive efficacy in the 4-aminopyridine and pilocarpine rat models of seizures. In this study, we examined whether isovaline possess therapeutic utility in a well-established rat model of infantile spasms which involves the pretreatment of a pregnant dam with betamethasone and subsequent induction of spasms with N-methyl-D-asparate (NMDA), a glutamate receptor agonist, in 15-day old pups. We treated seven of these pups with saline prior to administering NMDA and eight of these pups with isovaline (300 mg/kg) intraperitoneal (i.p.) prior to NMDA. Isovaline significantly reduced the number of full-body jumps from 18.1 ± 5.0 to 6.3 ± 1.8 and leg/arm/tail strains from 4.4 ± 1.6 to 1.1 ± 0.5. A trend in a reduction of body twitch was noted in rat pups administered isovaline (P = 0.05), but no significant difference was seen in NMDA-induced head nods (P = 0.221). In conclusion, our data demonstrate a potential for isovaline to attenuate an aggressive form of epilepsy that typically requires highly toxic medications to treat in children.
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:29Drug Dosing: Infants and Children